Merial GmbH, Kathrinenhof Research Center, Walchenseestr.8-12, 83101 Rohrdorf, Germany.
Vet Parasitol. 2013 Mar 1;192(4):338-45. doi: 10.1016/j.vetpar.2012.11.040. Epub 2012 Dec 7.
The therapeutic efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated against induced infections of developing fourth-stage larval or adult gastrointestinal and pulmonary nematodes of cattle in a series of six studies under two identical protocols (three each for developing fourth-stage larvae or adults) conducted in the USA, Germany or the UK (two studies at each location, one per stage). Each study initially included 16 nematode-free cattle. The cattle were of various breeds or crosses, weighed 109-186.5 kg prior to treatment, and were approximately 4-7 months old. The animals were blocked based on pre-treatment bodyweight and then randomly allocated to treatment: eprinomectin ERI vehicle (control) at 1 mL/50 kg body weight or eprinomectin 5% ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg) for a total of eight and eight animals in each group. Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. In each study, cattle were infected with a combination of infective third-stage larvae or eggs of gastrointestinal and pulmonary nematodes. Inoculation was scheduled so that the nematodes were expected to be fourth-stage larvae or adults at the time of treatment. For parasite recovery, all study animals were humanely euthanized and necropsied 14-15 (adult infections) or 21-22 days after treatment (developing fourth-stage larval infections). When compared with the vehicle-treated control counts, efficacy of eprinomectin ERI against developing fourth-stage larvae and adults was ≥98% (p<0.05) for the following nematodes: Dictyocaulus viviparus, Bunostomum phlebotomum, Cooperia curticei, C. oncophora, C. surnabada, C. punctata, Haemonchus contortus, H. placei, Nematodirus helvetianus, Oesophagostomum radiatum, Oes. venulosum, Ostertagia leptospicularis, O. ostertagi, O. circumcincta, O. pinnata, O. trifurcata (developing fourth-stage larval infections only), Strongyloides papillosus, Trichostrongylus axei, T. colubriformis, and Trichuris ovis (adult infections only). All animals accepted the treatment well. No adverse reaction to treatments was observed in any animal in any study.
在两项相同方案(每个阶段各有两项研究,每个地点各有一项研究)下,在美、德或英进行的 6 项研究中,评估了以埃普里诺菌素长效注射剂(ERI)制剂进行治疗对诱导的牛第四期幼虫或成体胃肠道和肺线虫感染的疗效。最初每一项研究均纳入 16 头无线虫牛。牛的品种或杂交品种各异,治疗前体重为 109-186.5 千克,年龄约为 4-7 月龄。动物基于预处理体重进行分组,然后随机分配至治疗组:埃普里诺菌素 ERI 载体(对照),剂量为 1 mL/50 kg 体重或埃普里诺菌素 5% ERI,剂量为 1 mL/50 kg 体重(1.0 mg 埃普里诺菌素/千克),每组各 8 头和 8 头动物。在第 0 天,通过肩部前方的皮下注射一次给予治疗。在每项研究中,牛均感染了胃肠道和肺线虫的感染性第三期幼虫或卵的混合物。接种时间安排使得线虫在治疗时处于第四期幼虫或成虫阶段。为了寄生虫回收,所有研究动物均通过人道方式安乐死并进行尸检,时间为治疗后 14-15 天(成虫感染)或 21-22 天(第四期幼虫发育感染)。与载体处理的对照组相比,埃普里诺菌素 ERI 对发育中的第四期幼虫和成虫的疗效≥98%(p<0.05),针对以下线虫:网尾线虫、双腔吸虫、细颈线虫、辐射食道口线虫、奥斯特线虫、哥伦比亚食道口线虫、点状食道口线虫、捻转血矛线虫、无齿食道口线虫、辐射食道口线虫、细颈食道口线虫、网尾线虫、奇异食道口线虫、脆弱双腔吸虫、毛圆线虫、捻转毛线虫和奥斯特线虫(仅第四期幼虫发育感染)、脆弱双腔吸虫、毛圆线虫、捻转毛线虫和奥斯特线虫(仅成虫感染)。所有动物均很好地接受了治疗。在任何研究中,任何动物均未观察到与治疗相关的不良反应。